By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sutro Biopharma 

310 Utah Avenue
Suite 150
South San Francisco  California  94080  U.S.A.
Phone: 650-392-8412 Fax: 650-872-8924


SEARCH JOBS

Sutro Biopharma, Inc. develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Sutro’s discovery and development efforts are driven by the Xpress CF™ platform, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro’s make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks, enabling broader and deeper biologics discovery and development efforts than can be accomplished with current cell-based expression technologies. Sutro’s technology platform allows production of proteins by bypassing the cell completely, cutting the pre-clinical development period by several months and can be done on any scale in just 8-10 hours.

Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.

In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics. Last year, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion. In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.

Key Management:

• William J. Newell, JD, CEO
• Trevor Hallam, PhD, Chief Scientific Officer
• Ed Albini, Chief Financial Officer
• Henry Heinsohn, VP Development & Manufacturing
• Aaron Sato, PhD, VP Research
• Nicki Vasquez, PhD, VP Alliance/Project Management

Interested in joining Sutro? Check us out on Linkedin @


Key Statistics


Email: busdev@sutrobio.com
Ownership: Private

Web Site: Sutro Biopharma
Employees: 80
Symbol: 
 




Segment
Biotherapeutics





Company News
NimbleGen Systems, Inc. Cofounder Launches Invenra, A Competitor For Sutro Biopharma 11/5/2014 6:23:16 AM
SSF's Sutro Biopharma Forges $1 Billion+ And Option To Buy Pact With Celgene (CELG) 10/23/2014 6:22:26 AM
South San Francisco's Sutro Biopharma Forges $375 Million Antibody Drug Pact With Merck KGaA (MKGAF.PK) 9/17/2014 6:27:52 AM
Sutro Biopharma To Collaborate With University of California, San Francisco (UCSF), A Recombinant Antibody Network (RAN) Member 9/9/2014 9:07:22 AM
Sutro Biopharma To Present At 21st Annual Future Leaders In The Biotech Industry Conference 3/25/2014 6:53:09 AM
Bay Area-Based Sutro Biopharma Scores $26 Million Financing From Big Name Biopharmas 12/11/2013 7:15:13 AM
Sutro Biopharma Presents Dual-Warhead Antibody Drug Conjugate at the World ADC Summit 10/16/2013 6:21:12 AM
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer 1/31/2013 7:41:00 AM
Sutro Biopharma to Collaborate With Sanofi Pasteur (SASY.PA) on a Novel Production Approach for Vaccine Candidates 1/3/2013 10:00:23 AM
Celgene Corporation (CELG), Sutro Biopharma Deal Could be Worth Over $500 Million 12/18/2012 7:57:44 AM
123
//-->